“…Generalised linear mixed (GLM) models were created with respect to each predictor and outcome and were performed using the SAS ‘GLIMMIX’ procedure to account for both interindividual and intraindividual effects. A regression model was created based on clinical relevance and included the following covariates: Systemic Lupus International collaborating Clinics/American College of Rheumatology Damage Index (SDI) 27 score (modified to exclude CD), Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) 28 score, presence of additional CD risk factors not captured elsewhere (hypertension, obesity and/or active smoker), antiphospholipid antibody positivity (lupus anticoagulant, anti-cardiolipin), azathioprine use (azathioprine use and dose were singled out from other immunomodulators due to its significance in previous research, 29 use of other immunomodulators (antimalarials, belimumab, calcineurin inhibitor, cyclophosphamide, methotrexate, mycophenolate, rituximab), Beck Depression Inventory score-II (BDI-II), 30 Beck Anxiety Inventory score (BAI), 31 age in years, sex (male vs female), ethnicity (black, Caucasian, Chinese vs other), employment status (employed or full-time student vs other), marital status (married or common-law partner vs other) and education level (completion of a College or University degree vs not).…”